0001104659-22-025658.txt : 20220222 0001104659-22-025658.hdr.sgml : 20220222 20220222162147 ACCESSION NUMBER: 0001104659-22-025658 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220217 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220222 DATE AS OF CHANGE: 20220222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Astria Therapeutics, Inc. CENTRAL INDEX KEY: 0001454789 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37467 FILM NUMBER: 22658368 BUSINESS ADDRESS: STREET 1: 100 HIGH STREET STREET 2: 28TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-349-1971 MAIL ADDRESS: STREET 1: 100 HIGH STREET STREET 2: 28TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: CATABASIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20090127 8-K 1 tm227201d1_8k.htm FORM 8-K
0001454789 false 0001454789 2022-02-17 2022-02-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 17, 2022

 

Astria Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-37467   26-3687168
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer Identification No.)

 

100 High Street, 28th Floor    
Boston, Massachusetts   02110
(Address of Principal Executive
Offices)
  (Zip Code)

 

Registrant’s telephone number, including area code: (617) 349-1971

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.001 per share   ATXS   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company               ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ¨

 

 

 

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

2022 Inducement Stock Incentive Plan

 

On February 17, 2022, the Board of Directors of Astria Therapeutics, Inc. (the “Company”) adopted, upon recommendation of the compensation committee of the Company’s Board of Directors (the “Committee”), the 2022 Inducement Stock Incentive Plan (the “Inducement Plan”), to be effective immediately. The Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards (collectively, the “stock awards”) with respect to an aggregate of 300,000 shares of common stock, $0.001 par value per share, of the Company (“Common Stock”) (subject to adjustment as provided in the Inducement Plan). Awards under the Inducement Plan may only be granted to persons who (a) were not previously an employee or director of the Company or (b) are commencing employment with the Company following a bona fide period of non-employment, in either case as an inducement material to the individual’s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). A complete copy of the Inducement Plan is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

Nonstatutory Stock Option Agreement

 

On February 17, 2022, the Company’s Board of Directors adopted, upon recommendation of the Committee, the Nonstatutory Stock Option Agreement (the “Agreement”) for use in the grant of stock options pursuant to the Inducement Plan. All stock options under the Inducement Plan shall be nonstatutory stock options. A complete copy of the form of Agreement is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein.

 

 

 

 

Item 9.01.Exhibits.

 

Exhibits

 

Number   Description
99.1   2022 Inducement Stock Incentive Plan
99.2   Form of Nonstatutory Stock Option Agreement under the 2022 Inducement Stock Incentive Plan
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ASTRIA THERAPEUTICS, INC.
   
Date: February 22, 2022 By:  /s/ Ben Harshbarger
    Ben Harshbarger
    Chief Legal Officer  

 

 

 

EX-99.1 2 tm227201d1_ex99-1.htm EXHIBIT 99.1

 Exhibit 99.1

 

 

ASTRIA THERAPEUTICS, INC.

 

2022 INDUCEMENT STOCK INCENTIVE PLAN

 

1.            Purpose

 

The purpose of this 2022 Inducement Stock Incentive Plan (the “Plan”) of Astria Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company with an inducement material for such persons to enter into employment with the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires, the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations thereunder (the “Code”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the “Board”).

 

2.            Eligibility

 

Awards under the Plan may only be granted to persons who (a) were not previously an employee or director of the Company or (b) are commencing employment with the Company following a bona fide period of non-employment, in either case as an inducement material to the individual’s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). For the avoidance of doubt, neither consultants nor advisors shall be eligible to participate in the Plan. Each person who is granted an Award under the Plan is deemed a “Participant.” The Plan provides for the following types of awards, each of which is referred to as an “Award”:  Options (as defined in Section 5), SARs (as defined in Section 6), Restricted Stock (as defined in Section 7), Restricted Stock Units (as defined in Section 7) and Other Stock-Based Awards (as defined in Section 8).

 

3.            Administration and Delegation

 

(a)            Administration by Board of Directors. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient and it shall be the sole and final judge of such expediency. All decisions by the Board with respect to the Plan and any Awards shall be made in the Board’s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. The Board may delegate administration of the Plan to a Committee or Committees (as defined in Section 3(b)), as provided in Section 3(b). Notwithstanding the foregoing or anything in the Plan to the contrary, the grant of any Award under the Plan must be approved by the Company’s independent compensation committee or a majority of the Company’s independent directors (as defined in Nasdaq Stock Market Rule 5605(a)(2)) in order to comply with the exemption from the stockholder approval requirement for “inducement grants” provided under Nasdaq Stock Market Rule 5635(c)(4).

 

 

 

 

 

(b)            Appointment of Committees. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a “Committee”). All references in the Plan to the “Board” shall mean the Board or a Committee of the Board or the officers referred to in Section 3(c) to the extent that the Board’s powers or authority under the Plan have been delegated to such Committee or officers.

 

(c)            Delegation to Officers. Subject to any requirements of applicable law (including as applicable Sections 152 and 157(c) of the General Corporation Law of the State of Delaware) and applicable Nasdaq Stock Market rules, the Board may delegate to one or more officers of the Company the power to grant Awards (subject to any limitations under the Plan) officers of the Company and to exercise such other powers under the Plan as the Board may determine, provided that the Board shall fix the terms of Awards to be granted by such officers, the maximum number of shares subject to Awards that the officers may grant, and the time period in which such Awards may be granted; and provided further, that no officer shall be authorized to grant Awards to any “executive officer” of the Company (as defined in Rule 3b-7 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) or to any “officer” of the Company (as defined by Rule 16a-1(f) under the Exchange Act).

 

4.            Stock Available for Awards

 

(a)            Number of Shares; Share Counting.

 

(1)            Authorized Number of Shares. Subject to adjustment under Section 9, Awards may be made under the Plan for up to 300,000 shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”). Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares.

 

(2)            Share Counting. For purposes of counting the number of shares available for the grant of Awards under the Plan:

 

(A)            all shares of Common Stock covered by SARs shall be counted against the number of shares available for the grant of Awards under the Plan; provided, however, that (i) SARs that may be settled only in cash shall not be so counted and (ii) if the Company grants an SAR in tandem with an Option for the same number of shares of Common Stock and provides that only one such Award may be exercised (a “Tandem SAR”), only the shares covered by the Option, and not the shares covered by the Tandem SAR, shall be so counted, and the expiration of one in connection with the other’s exercise will not restore shares to the Plan;

 

 

 

 

 

(B)             if any Award (i) expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or (ii) results in any Common Stock not being issued (including as a result of an SAR that was settleable either in cash or in stock actually being settled in cash), the unused Common Stock covered by such Award shall again be available for the grant of Awards; provided, however, that (1) in the case of the exercise of an SAR, the number of shares counted against the shares available under the Plan shall be the full number of shares subject to the SAR multiplied by the percentage of the SAR actually exercised, regardless of the number of shares actually used to settle such SAR upon exercise and (2) the shares covered by a Tandem SAR shall not again become available for grant upon the expiration or termination of such Tandem SAR; and

 

(C)            shares of Common Stock delivered (either by actual delivery, attestation, or net exercise) to the Company by a Participant to (i) purchase shares of Common Stock upon the exercise of an Award or (ii) satisfy tax withholding obligations with respect to Awards (including shares retained from the Award creating the tax obligation) shall be added back to the number of shares available for the future grant of Awards.

 

5.            Stock Options

 

(a)            General. The Board may grant options to purchase Common Stock (each, an “Option”) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. All Options under the Plan shall be Nonstatutory Stock Options. A “Nonstatutory Stock Option” is an Option which is not intended to be an “incentive share option” within the meaning of Section 422 of the Code.

 

(b)            Exercise Price. The Board shall establish the exercise price of each Option and specify the exercise price in the applicable Option agreement. The exercise price shall be not less than 100% of the Grant Date Fair Market Value (as defined below) of the Common Stock on the date the Option is granted; provided that if the Board approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall be not less than 100% of the Grant Date Fair Market Value on such future date. “Grant Date Fair Market Value” of a share of Common Stock for purposes of the Plan will be determined as follows:

 

(1)            if the Common Stock trades on a national securities exchange, the closing sale price (for the primary trading session) on the date of grant; or

 

 

 

 

 

(2)            if the Common Stock does not trade on any such exchange, the average of the closing bid and asked prices on the date of grant as reported by an over-the-counter marketplace designated by the Board; or

 

(3)            if the Common Stock is not publicly traded, the Board will determine the Grant Date Fair Market Value for purposes of the Plan using any measure of value it determines to be appropriate (including, as it considers appropriate, relying on appraisals) in a manner consistent with the valuation principles under Code Section 409A.

 

For any date that is not a trading day, the Grant Date Fair Market Value of a share of Common Stock for such date will be determined by using the closing sale price or average of the bid and asked prices, as appropriate, for the immediately preceding trading day and with the timing in the formulas above adjusted accordingly.  The Board can substitute a particular time of day or other measure of “closing sale price” or “bid and asked prices” if appropriate because of exchange or market procedures or can, in its sole discretion, use weighted averages either on a daily basis or such longer period as is consistent with Code Section 409A.

 

The Board has sole discretion to determine the Grant Date Fair Market Value for purposes of the Plan, and all Awards are conditioned on the participants’ agreement that the Board’s determination is conclusive and binding even though others might make a different determination.

 

(c)            Duration of Options. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable Option agreement; provided, however, that no Option will be granted with a term in excess of 10 years.

 

(d)            Exercise of Options. Options may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with payment in full (in the manner specified in Section 5(e)) of the exercise price for the number of shares for which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by the Company as soon as practicable following exercise.

 

(e)            Payment Upon Exercise. Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:

 

(1)            in cash or by check, payable to the order of the Company;

 

(2)            except as may otherwise be provided in the applicable Option agreement or approved by the Board, in its sole discretion, by (i) delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding;

 

 

 

 

 

(3)            to the extent provided for in the applicable Option agreement or approved by the Board, in its sole discretion and subject to compliance with applicable law, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their fair market value (valued in the manner determined by (or in the manner approved by) the Board), provided (i) such method of payment is then permitted under applicable law, (ii) such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements;

 

(4)            to the extent provided for in the applicable Nonstatutory Stock Option agreement or approved by the Board in its sole discretion and subject to compliance with applicable law, by delivery of a notice of “net exercise” to the Company, as a result of which the Participant would receive (i) the number of shares underlying the portion of the Option being exercised, less (ii) such number of shares as is equal to (A) the aggregate exercise price for the portion of the Option being exercised divided by (B) the fair market value of a share of Common Stock (valued in the manner determined by (or in the manner approved by) the Board) on the date of exercise;

 

(5)            to the extent permitted by applicable law and provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by payment of such other lawful consideration as the Board may determine; or

 

(6)            by any combination of the above permitted forms of payment, as approved by the Board.

 

(f)            Limitation on Repricing. Unless such action is approved by the Company’s stockholders, the Company may not (except as provided for under Section 9): (1) amend any outstanding Option granted under the Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Option, (2) cancel any outstanding option (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled option, (3) cancel in exchange for a cash payment any outstanding Option with an exercise price per share above the then-current fair market value of a share of Common Stock (valued in the manner determined by (or in the manner approved by) the Board), or (4) take any other action under the Plan that constitutes a “repricing” within the meaning of the rules of the Nasdaq Stock Market (“Nasdaq”).

 

(g)            No Dividend Equivalents. No Option shall provide for the payment or accrual of dividend equivalents.

 

 

 

 

 

6.            Stock Appreciation Rights

 

(a)            General. The Board may grant Awards consisting of stock appreciation rights (“SARs”) entitling the holder, upon exercise, to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the Board) determined by reference to appreciation, from and after the date of grant, in the Fair Market Value of a share of Common Stock over the measurement price established pursuant to Section 6(b). The date as of which such appreciation is determined shall be the exercise date.

 

(b)            Measurement Price. The Board shall establish the measurement price of each SAR and specify it in the applicable SAR agreement. The measurement price shall not be less than 100% of the Grant Date Fair Market Value of a share of Common Stock on the date the SAR is granted; provided that if the Board approves the grant of an SAR effective as of a future date, the measurement price shall be not less than 100% of the Grant Date Fair Market Value on such future date.

 

(c)            Duration of SARs. Each SAR shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable SAR agreement; provided, however, that no SAR will be granted with a term in excess of 10 years.

 

(d)            Exercise of SARs. SARs may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with any other documents required by the Board.

 

(e)            Limitation on Repricing. Unless such action is approved by the Company’s stockholders, the Company may not (except as provided for under Section 9): (1) amend any outstanding SAR granted under the Plan to provide a measurement price per share that is lower than the then-current measurement price per share of such outstanding SAR, (2) cancel any outstanding SAR (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan covering the same or a different number of shares of Common Stock and having an exercise or measurement price per share lower than the then-current measurement price per share of the cancelled SAR, (3) cancel in exchange for a cash payment any outstanding SAR with a measurement price per share above the then-current fair market value of a share of Common Stock (valued in the manner determined by (or in the manner approved by) the Board), or (4) take any other action under the Plan that constitutes a “repricing” within the meaning of the rules of Nasdaq.

 

(f)            No Dividend Equivalents. No SAR shall provide for the payment or accrual of dividend equivalents.

 

7.            Restricted Stock; Restricted Stock Units

 

(a)            General. The Board may grant Awards entitling recipients to acquire shares of Common Stock (“Restricted Stock”), subject to the right of the Company to repurchase (in accordance with applicable law and the Award agreement) all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards entitling the recipient to receive shares of Common Stock or cash to be delivered at the time such Award vests (“Restricted Stock Units”) (Restricted Stock and Restricted Stock Units are each referred to herein as a “Restricted Stock Award”).

 

 

 

 

 

(b)            Terms and Conditions for All Restricted Stock Awards. The Board shall determine the terms and conditions of a Restricted Stock Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any.

 

(c)            Additional Provisions Relating to Restricted Stock.

 

(1)            Dividends. Any dividends (whether paid in cash, stock or property) declared and paid by the Company with respect to shares of Restricted Stock (“Accrued Dividends”) shall be paid to the Participant only if and when such shares become free from the restrictions on transferability and forfeitability that apply to such shares. Each payment of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day of the third month following the lapsing of the restrictions on transferability and the forfeitability provisions applicable to the underlying shares of Restricted Stock.

 

(2)            Stock Certificates. The Company may require that any stock certificates issued in respect of shares of Restricted Stock, as well as dividends or distributions paid on such Restricted Stock, shall be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the expiration of the applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to his or her Designated Beneficiary. “Designated Beneficiary” means (i) the beneficiary designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant’s death or (ii) in the absence of an effective designation by a Participant, the Participant’s estate.

 

(d)            Additional Provisions Relating to Restricted Stock Units.

 

(1)            Settlement. Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with respect to each Restricted Stock Unit, the Participant shall be entitled to receive from the Company such number of shares of Common Stock or (if so provided in the applicable Award agreement or otherwise determined by the Board) an amount of cash equal to the fair market value (valued in the manner determined by (or in the manner approved by) the Board) of such number of shares of Common Stock as are set forth in the applicable Restricted Stock Unit agreement, or a combination thereof. The Board may, in its discretion, provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with Section 409A of the Code or any successor provision thereto, and the regulations thereunder (“Section 409A”).

 

 

 

 

 

(2)            Voting Rights. A Participant shall have no voting rights with respect to any Restricted Stock Units.

 

(3)            Dividend Equivalents. The Award agreement for Restricted Stock Units may provide Participants with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (“Dividend Equivalents”). Dividend Equivalents shall be credited to an account for the Participant, may be settled in cash and/or shares of Common Stock as set forth in the applicable Award agreement, and shall be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which paid.

 

8.            Other Stock-Based Awards

 

(a)            General. Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property, may be granted hereunder to Participants (“Other Stock-Based Awards”). Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine.

 

(b)            Terms and Conditions. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other Stock-Based Award, including any purchase price applicable thereto.

 

(c)            Dividend Equivalents. The Award agreement for Other Stock-Based Awards may provide Participants with the right to receive Dividend Equivalents. Dividend Equivalents shall be credited to an account for the Participant, may be settled in cash and/or shares of Common Stock as set forth in the applicable Award agreement, and shall be subject to the same restrictions on transfer and forfeitability as the Other Stock-Based Awards with respect to which paid.

 

9.            Adjustments for Changes in Common Stock and Certain Other Events

 

(a)            Changes in Capitalization. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i) the number and class of securities available under the Plan, (ii) the share counting rules set forth in Section 4(a), (iii) the number and class of securities and exercise price per share of each outstanding Option, (iv) the share and per-share provisions and the measurement price of each outstanding SAR, (v) the number of shares subject to and the repurchase price per share subject to each outstanding Restricted Stock Award and (vi) the share and per-share-related provisions and the purchase price, if any, of each outstanding Other Stock-Based Award, shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board. Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend.

 

 

 

 

 

(b)            Reorganization Events.

 

(1)            Definition. A “Reorganization Event” shall mean: (a) any merger or consolidation of the Company with or into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any transfer or disposition of all of the Common Stock of the Company for cash, securities or other property pursuant to a share exchange or other transaction or (c) any liquidation or dissolution of the Company.

 

(2)            Consequences of a Reorganization Event on Awards Other than Restricted Stock.

 

(A)            In connection with a Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards other than Restricted Stock on such terms as the Board determines (except to the extent specifically provided otherwise in an applicable Award agreement or another agreement between the Company and the Participant): (i) provide that such Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to a Participant, provide that all of the Participant’s unvested and/or unexercised Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable) within a specified period following the date of such notice, (iii) provide that outstanding Awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv) in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the “Acquisition Price”), make or provide for a cash payment to Participants with respect to each Award held by a Participant equal to (A) the number of shares of Common Stock subject to the vested portion of the Award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization Event) multiplied by (B) the excess, if any, of (I) the Acquisition Price over (II) the exercise, measurement or purchase price of such Award and any applicable tax withholdings, in exchange for the termination of such Award, (v) provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and (vi) any combination of the foregoing. In taking any of the actions permitted under this Section 9(b)(2), the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically.

 

 

 

 

 

(B)            Notwithstanding the terms of Section 9(b)(2)(A), in the case of outstanding Restricted Stock Units that are subject to Section 409A: (i) if the applicable Restricted Stock Unit agreement provides that the Restricted Stock Units shall be settled upon a “change in control event” within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i), and the Reorganization Event constitutes such a “change in control event”, then no assumption or substitution shall be permitted pursuant to Section 9(b)(2)(A)(i) and the Restricted Stock Units shall instead be settled in accordance with the terms of the applicable Restricted Stock Unit agreement; and (ii) the Board may only undertake the actions set forth in clauses (iii), (iv) or (v) of Section 9(b)(2)(A) if the Reorganization Event constitutes a “change in control event” as defined under Treasury Regulation Section 1.409A-3(i)(5)(i) and such action is permitted or required by Section 409A; if the Reorganization Event is not a “change in control event” as so defined or such action is not permitted or required by Section 409A, and the acquiring or succeeding corporation does not assume or substitute the Restricted Stock Units pursuant to clause (i) of Section 9(b)(2)(A), then the unvested Restricted Stock Units shall terminate immediately prior to the consummation of the Reorganization Event without any payment in exchange therefor.

 

(C)            For purposes of Section 9(b)(2)(A)(i), an Award (other than Restricted Stock) shall be considered assumed if, following consummation of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for each share of Common Stock subject to the Award immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise or settlement of the Award to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event.

 

(3)            Consequences of a Reorganization Event on Restricted Stock. Upon the occurrence of a Reorganization Event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit of the Company’s successor and shall, unless the Board determines otherwise, apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to such Restricted Stock; provided, however, that the Board may provide for termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, either initially or by amendment. Upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Stock then outstanding shall automatically be deemed terminated or satisfied.

 

 

 

 

 

10.            General Provisions Applicable to Awards

 

(a)            Transferability of Awards. Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or pursuant to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant; provided, however, that, except with respect to Awards subject to Section 409A, the Board may permit or provide in an Award for the gratuitous transfer of the Award by the Participant to or for the benefit of any immediate family member, family trust or other entity established for the benefit of the Participant and/or an immediate family member thereof if the Company would be eligible to use a Form S-8 under the Securities Act of 1933, as amended, for the registration of the sale of the Common Stock subject to such Award to such proposed transferee; provided further, that the Company shall not be required to recognize any such permitted transfer until such time as such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of the Award. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees. For the avoidance of doubt, nothing contained in this Section 10(a) shall be deemed to restrict a transfer to the Company.

 

(b)            Documentation; Press Release. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan. Promptly following the grant of an Award hereunder, the Company must disclose in a press release the material terms of the grant, the number of shares involved, and, if required by law or Nasdaq rules, the identity of the Participant and each Participant, by accepting the Award, consents to the foregoing.

 

(c)            Board Discretion. Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly.

 

(d)            Termination of Status. The Board shall determine the effect on an Award of the disability, death, termination or other cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant’s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights, or receive any benefits, under an Award.

 

 

 

 

 

(e)            Withholding. The Participant must satisfy all applicable federal, state, and local or other income and employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may elect to satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or purchase price, unless the Company determines otherwise. If provided for in an Award or approved by the Board in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their fair market value (valued in the manner determined by (or in the manner approved by) the Company); provided, however, except as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company’s minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income) except that, to the extent that the Company is able to retain shares of Common Stock having a fair market value (determined by, or in a manner approved by, the Company) that exceeds the statutory minimum applicable withholding tax without financial accounting implications or the Company is withholding in a jurisdiction that does not have a statutory minimum withholding tax, the Company may retain such number of shares of Common Stock (up to the number of shares having a fair market value equal to the maximum individual statutory rate of tax (determined by, or in a manner approved by, the Company)) as the Company shall determine in its sole discretion to satisfy the tax liability associated with any Award. Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements.

 

(f)            Amendment of Award. Except as otherwise provided in Sections 5(f) and 6(e) with respect to repricings, the Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type and changing the date of exercise or realization; provided that no amendment that would require stockholder approval under the rules of Nasdaq may be made effective unless and until the Company’s stockholders approve such amendment. The Participant’s consent to such action shall be required unless (i) the Board determines that the action, taking into account any related action, does not materially and adversely affect the Participant’s rights under the Plan or (ii) the change is permitted under Section 9.

 

(g)            Conditions on Delivery of Stock. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously issued or delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the Company, (ii) in the opinion of the Company’s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations.

 

 

 

 

 

(h)            Acceleration. The Board may at any time provide that any Award shall become immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be.

 

11.          Miscellaneous

 

(a)            No Right To Employment or Other Status. No person shall have any claim or right to be granted an Award by virtue of the adoption of the Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Award.

 

(b)            No Rights As Stockholder; Clawback. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of such shares. In accepting an Award under the Plan, the Participant agrees to be bound by any clawback policy that the Company has in effect or may adopt in the future.

 

(c)            Effective Date. The Plan shall become effective on the date on which it is adopted by the Board. It is expressly intended that approval of the Company’s stockholders not be required as a condition to the effectiveness of the Plan, and the Plan’s provisions shall be interpreted in a manner consistent with such intent for all purposes.

 

(d)            Amendment of Plan. The Board may amend, suspend or terminate the Plan or any portion thereof at any time, provided that no amendment that would require stockholder approval under the rules of Nasdaq may be made effective unless and until the Company’s stockholders approve such amendment. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section 11(d) shall apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of Participants under the Plan.

 

(e)            Authorization of Sub-Plans (including for Grants to non-U.S. Employees). The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable securities, tax or other laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to the Plan containing (i) such limitations on the Board’s discretion under the Plan as the Board deems necessary or desirable or (ii) such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement.

 

 

 

 

 

(f)            Compliance with Section 409A. Except as provided in individual Award agreements initially or by amendment, if and to the extent (i) any portion of any payment, compensation or other benefit provided to a Participant pursuant to the Plan in connection with his or her employment termination constitutes “nonqualified deferred compensation” within the meaning of Section 409A and (ii) the Participant is a specified employee as defined in Section 409A(a)(2)(B)(i), in each case as determined by the Company in accordance with its procedures, by which determinations the Participant (through accepting the Award) agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six months plus one day after the date of “separation from service” (as determined under Section 409A) (the “New Payment Date”), except as Section 409A may then permit. The aggregate of any payments that otherwise would have been paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original schedule.

 

The Company makes no representations or warranty and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under the Plan are determined to constitute nonqualified deferred compensation subject to Section 409A but do not satisfy the conditions of that section.

 

(g)            Limitations on Liability. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, employee or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan, nor will such individual be personally liable with respect to the Plan because of any contract or other instrument he or she executes in his or her capacity as a director, officer, employee or agent of the Company. The Company will indemnify and hold harmless each director, officer, employee or agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including attorneys’ fees) or liability (including any sum paid in settlement of a claim with the Board’s approval) arising out of any act or omission to act concerning the Plan unless arising out of such person’s own fraud or bad faith.

 

(h)            Governing Law. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than the State of Delaware.

 

 

 

EX-99.2 3 tm227201d1_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

 

 

 

ASTRIA THERAPEUTICS, INC.
Nonstatutory STOCK OPTION AGREEMENT

 

Granted Under 2022 Inducement Stock Incentive Plan

 

Astria Therapeutics, Inc. (the “Company”) hereby grants the following stock option to the Participant listed below pursuant to the Company’s 2022 Inducement Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof.

 

Notice of Grant

 

Name of optionee (the “Participant”):  
Grant Date:  
Number of shares of the Company’s Common Stock subject to this option (“Shares”):  
Option exercise price per Share:  
Number, if any, of Shares that vest immediately on the grant date: N/A
Shares that are subject to vesting schedule:  
Vesting Commencement Date:  
Final Exercise Date:  

 

Vesting Schedule:

 

Date Options Vesting
   
   
All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.

 

This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.

 

 

 

ASTRIA PHARMACEUTICALS, INC.

 

Nonstatutory Stock Option Agreement

Granted Under 2022 Inducement Stock Incentive Plan

Incorporated Terms and Conditions

 

1.            Grant of Option.

 

This agreement evidences the grant by the Company, on the grant date (the “Grant Date”) set forth in the Notice of Grant that forms part of this agreement (the “Notice of Grant”) to the Participant of an option to purchase, in whole or in part, on the terms provided herein and in the Company’s 2022 Inducement Stock Incentive Plan (the “Plan”), the number of Shares set forth in the Notice of Grant of common stock, $0.001 par value per share, of the Company (“Common Stock”) at the exercise price per Share set forth in the Notice of Grant. Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant (the “Final Exercise Date”).

 

The option evidenced by this agreement was granted to the Participant pursuant to the inducement grant exception under Nasdaq Stock Market Rule 5635(c)(4) as an inducement that is material to the Participant’s employment with the Company.

 

It is intended that the option evidenced by this agreement shall not be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). Except as otherwise indicated by the context, the term “Participant”, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.

 

2.            Vesting Schedule.

 

This option will become exercisable (“vest”) in accordance with the vesting schedule set forth in the Notice of Grant (the “Vesting Schedule”). Notwithstanding the foregoing, to the extent that the Participant is a party to an employment agreement or other agreement with the Company that provides vesting terms that differ from the Vesting Schedule, the terms set forth in such employment agreement or other agreement shall prevail.

 

The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof.

 

3.            Exercise of Option.

 

(a)            Form of Exercise. Each election to exercise this option shall be in writing in the form attached hereto as Exhibit A, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, and payment in full in the manner provided in the Plan. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten whole shares.

 

- 2 -

 

 

(b)            Continuous Relationship with the Company Required. Except as otherwise provided in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, officer or director of, or consultant to, the Company or any other entity the service providers of which are eligible to receive option grants under the Plan (an “Eligible Participant”).

 

(c)            Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate three months after such cessation (but in no event after the Final Exercise Date), provided that this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon written notice to the Participant from the Company describing such violation.

 

(d)            Exercise Period Upon Death or Disability. If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for “cause” as specified in paragraph (e) below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), provided that this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.

 

(e)            Termination for Cause.  If, prior to the Final Exercise Date, the Participant’s employment or other relationship with the Company is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other relationship.  “Cause” shall mean, in the good faith determination of the Company, the Participant has: (i) committed gross negligence or willful malfeasance in the performance of the Participant’s work or duties; (ii) committed a breach of fiduciary duty or a breach of any non-competition, non-solicitation or confidentiality obligations to the Company; (ii) failed to follow the proper directions of the Participant’s direct or indirect supervisor after written notice of such failure; (iii) been convicted of, or pleaded “guilty” or “no contest” to, any misdemeanor relating to the affairs of the Company or any felony; (iv) disregarded the material rules or material policies of the Company which has not been cured within 15 days after notice thereof from the Company; or (v) engaged in intentional acts that have generated material adverse publicity toward or about the Company.

 

4.            Withholding.

 

No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.

 

- 3 -

 

 

5.            Nontransferability of Option; Clawback.

 

This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant. In accepting this option, the Participant agrees to be bound by any clawback policy that the Company has adopted or may adopt in the future.

 

6.            Provisions of the Plan.

 

This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.

 

- 4 -

 

 

PARTICIPANT’S ACCEPTANCE

 

The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges receipt of a copy of the Company’s 2022 Inducement Stock Incentive Plan.

 

PARTICIPANT:
  
  
 Address:  
    
  
  
 PARTICIPANT’S SPOUSE (if applicable)*:
  
  
 Address:  
    
  
  
   ASTRIA THERAPEUTICS, INC.
  
  
   By:  
     Name:
     Title:

 

*            Required for Participants residing in Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas or Wisconsin.

 

- 5 -

 

 

EXHIBIT A

 

ASTRIA THERAPEUTICS, INC.

 

Stock Option Exercise Notice

 

Astria Therapeutics, Inc.
100 High Street

28th Floor

Boston, MA 02210

 

Dear Sir or Madam:

 

I am the holder of a Nonstatutory Stock Option granted to me under the Astria Therapeutics, Inc. (the “Company”) 2022 Inducement Stock Incentive Plan on ________ for the purchase of ________ shares of Common Stock of the Company at a purchase price of $ ________ per share.

 

I hereby exercise my option to purchase ________ shares of Common Stock (the “Shares”), for which I have enclosed [cash] [a personal check] in the amount of ________ . Please register my stock certificate as follows:

 

Dated:_____________________________  

 

__________________________________

Signature
Print Name:

 

Address:

___________________________________

___________________________________

 

Name and address of persons in whose name the Shares are to be jointly registered (if applicable):

 

___________________________________

___________________________________ Tax ID#

 

Very truly yours,

 

_____________________________

 

- 6 -

 

EX-101.SCH 4 atxs-20220217.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 atxs-20220217_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 atxs-20220217_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm227201d1_ex99-2img001.jpg GRAPHIC begin 644 tm227201d1_ex99-2img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# H'!PD'!@H)" D+"PH,#QD0#PX. M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_ MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P 1" !# +8# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V:BBH;F9X M8P8HO,=B% S@#W)["@:5W8FJ!KVU601MWS-TX&:R[6^U6YAN'LH88(L;\16#E7R0,*SLN>.> !P M:VA1:VCX/TF6SCM[N.:\5',@:XF9F+ M$ $DY]A6U&BQH$4 >V*=4.K+H[&53%5)6L[)?UONZTR;L89 M2R'_ 'D8D$>UF#7IU8W MBS2O[6\/W"1_+;?$+XFRZ#>MI6BK& MUX@!GGD&Y8L\A0.[8]>!_+QC(])HKP23Q9\0K. :CX]Q0!VE%>7_$'XBZEINNC0O#ZJMP MNT22E [%VZ(H/'<E0>$O$\7BW2'U"WMY((Q,T060@L<8YX^M>??%Y_$1#B1 M5'A_,14X3/F\_P# NM8G@R3QVF@L/"R(UCYK\L(OO\9^]SZ4#/>**\P^('C' MQ!X7.A"WGCCFFMBUU&\2LK.-N?IR3T-8,'C;Q]KMW#+9VUPEJTBY^S61*;?TKUVO)M;\=:] M9_$[^QX+N-;'[9#%Y9A4G:VW(SC/IX0MHX+:-)]2N 6C1_NQK_>; M^0'?\* .RHKP5/%OQ"U& ZA;/?O;#G?!9CR\>WR\C\ZZ[X??$^76[Y-)UP1B M[DSY%P@VB0_W6'9O3'!_F >F4444 8>KB2XU$62!C]H2(@\[4VNS$GZA^(=-LM5M=,GN!]LNCM2-1DCC@G'0&G"$INT5<#R^]:^/BK0CK,1CN_ ML,GG(JJA S-C ' ^7%=C\+C9GPM+]@6X6+[4_$[*6SM7T XKE!'96VMZ!:N9 M+N8VTL$=VLA1=V^52"C+DX)QU%;WP=EW>&;N+NEV3^:K_A7T>/7-A&TK6MY+ MXI=/\]C:>QZ!7@7AF.&]^,.-5 8F^G;:_0R#<5'Y@?D*]]KR3XC?#O4'UA]= M\/QO*TK"2:&(XD20?QIZYZX'.>:^:,3UET61&210R,,,K#((]#7@7@N6&P^+ M4,=@P^RFZG@CP>#&0V/Y#\JLIJ_Q'URW_LI4U JX\MV-L(3CI\TA Q^=5])\ M*ZUX7\>V'G:?=30VMS&7G@@9HRIQD@XZ#)_*@9T'Q%^'NL77B.76M%B-RDVU MWCC<+)&Z@#(SC/0'CG-8UG\2?%OAJ]2WUA9+A4QO@O(MDA7V; /XG-=SXPUO MQIHFOM)HVFB^TIHEP/)\PJW.[[I##MUKA-8@\8?$75;;[1HS6_D@HK&%HHXP M3R69N3TZ?D* .T^*=]%J?PTM[VW),-Q-!*F>N#DU/\&?^1';_K[D_I6CXA\& M'4/AZF@6D@\ZVBC\EWX#.F.OIGG\Z\S\/:CXW\%K/86FBW$B.Y?RI;5Y%#=, MJR^N!WQ0!K?'+_D):1_UQE_FM>F^%/\ D4='_P"O*'_T 5YM\3=)US7X/#]Q M%I=U-U>F>&H9+?POI<,\;1RQVD2NC#!4A0""* / M&?$G_):O^XA;?R2F_$?;/\5'COCBVW6Z-D\",A<_S:M/7_#NL3_%O[=#I=X] MG]N@?SUB)3:-F3GTI?$WP#-XD6/4]*56OX4V/$3CSDZC!_O#)Z]7/!,P3HLGREO\3]34UEK?Q$L M;==*MX=3PHV*'L]SH/0.1T_&LS6O WB73IH);BQN;N>Y3SW:%6E*ODY5V'\7 M0_C0!]&T5!93&YL;>9D9#)&K%7&"I(Z$=C10(E=0Z,IR 1C@X-<_=:4UZJPZ ME$95@!B#JF3<*Y ^8CM_>&.H# C KHJ9+<1OG:PP<$@_F*TIU'!W0T['" M6JW\&>0*LV6M>)X)+>*]6P=9)-@:= M'AD8#!8_+N0\'J#@UOZAI/FH6A@AFD:(Q2M*<.ZXXYP02/\ :!K.E\)01&,: M?'):J(\R>5*Z!SQQ\CJ >O;%>@L12FO?2U\O^#=?UUNR^9,Y:_\ %.M:M>7$ M&GZM MKO81_V=:R33,F>,G& <8[BM'PSH(TRZM[J2&Z@N9)B)I)I(Y)I.F-[ MYP@.?N#+'CG&:Z*'2?M( N+23R(8@D4-U,7WG).6PQ!_$$UIPZ?%&4+DS&/! M0R!258#&[..I'>G5QL%#V=-677;7[M_G\A.2V1Y5XP@_L34K.[$L;_8-5=V5 M,YC20K,JG(_W^F:W_ .HM%XIUW1I8K:,1/YD7DPK'N4,1D[1SPRFM;Q7X.;Q M \[0RQQBYMQ'*'!^^AW1.,>F64^S>U96G>!M8T_7-*U9;RS-S;Q""[&6Q,@^ M4$<==F!SW4&NAXFC6PO).7O6?W[_ )W7S0[IH[^BBBO",PHHHH 9+*D,3RRN MJ1HI9F8X"@=235*VU[2;TD6NIVI-7^O!KCYO#U_+I;6\: M&&1M;-T'C9-RQ><6WC.1G'."#]* .ENM6T^Q#F[OK: 1E5?S)57:2,@')[@' M%0MXBT=!"7U6Q43C,1-PHWC.,CGGD8KD]1\-:M'J,\\37MV/MMO,LZO )BJQ M2*V 0$X+ :-9Y06CC+ ,X'4@=3C(JJFN:7+<2P1ZE9M-"&,D8G4L@7[V1G MC'?TKE+[0MUUS2[WFTU&TG&X)^[F5OF.<#@]3 M@_E3KO6=-L-WVR_M;?:VP^;,JX; .#D]<$'Z&N6ATS5?[)LBUMJ$LUA3 M=/;@NJ@JPC,?'?/S'G YJ:[TC4-2T+Q$YLC%/J4JM!;R.I<*J1I\Q!*@G83C M/I0!TL>K:?- T\=];-$L?FLXE4J$R1N)STRIY]C4(\0:2UBUZNIV9M5;8THF M7:&],YZ^U8FOZ%>WFJW-S;VR30B.S81,X G\J61VCYZ<,I&>,X]Z=JD$^J6R MW/\ 8E_:317*R1R6\T*W((0KOP25/4K@D\&@#IK>XANH$GMY4EA<922-@RL/ M4$=:*H^'X[Z+1+=-31$NP&WA%4<;CC(7Y=V,9QQG.** -*BBB@ HHHH **** G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9 end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Feb. 17, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 17, 2022
Entity File Number 001-37467
Entity Registrant Name Astria Therapeutics, Inc.
Entity Central Index Key 0001454789
Entity Tax Identification Number 26-3687168
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 High Street
Entity Address, Address Line Two 28th Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 617
Local Phone Number 349-1971
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ATXS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 tm227201d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001454789 2022-02-17 2022-02-17 iso4217:USD shares iso4217:USD shares 0001454789 false 8-K 2022-02-17 Astria Therapeutics, Inc. DE 001-37467 26-3687168 100 High Street 28th Floor Boston MA 02110 617 349-1971 false false false false Common Stock, par value $0.001 per share ATXS NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://catabasis.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm227201d1_8k.htm atxs-20220217.xsd atxs-20220217_lab.xml atxs-20220217_pre.xml tm227201d1_ex99-1.htm tm227201d1_ex99-2.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm227201d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm227201d1_8k.htm" ] }, "labelLink": { "local": [ "atxs-20220217_lab.xml" ] }, "presentationLink": { "local": [ "atxs-20220217_pre.xml" ] }, "schema": { "local": [ "atxs-20220217.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atxs", "nsuri": "http://catabasis.com/20220217", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "b", "p", "body", "html" ], "baseRef": "tm227201d1_8k.htm", "contextRef": "From2022-02-17to2022-02-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://catabasis.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "b", "p", "body", "html" ], "baseRef": "tm227201d1_8k.htm", "contextRef": "From2022-02-17to2022-02-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://catabasis.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001104659-22-025658-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-025658-xbrl.zip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end